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Abstract: Background: Autoimmune atrophic gastritis (AAG) leads to iron and/or vitamin B12
malabsorption, with subsequent haematological alterations which could represent the sole clinical
manifestation. We aimed to assess patterns of anaemia and micronutrient deficiencies in patients
with AAG at the time of diagnosis. Methods: Observational, multicentre, cross-sectional study
including consecutive adult patients diagnosed with AAG within the last ten years. Cell blood count,
red cell distribution width, serum vitamin B12, and ferritin were collected. Multivariate analysis for
predictive factors of anaemia was computed. Results: 654 AAG patients (mean age 59.2 ± 13.8 years,
female (F): male (M) ratio = 2.3:1) were included. Anaemia was present in 316 patients (48.3%; mean age
60.1 ± 15.8 years, F:M ratio = 2.3:1). Pernicious anaemia (132/316 cases, 41.7%) was more common in males
(27.1% versus 12.4%; p = 0.001) and in older patients (63.0 ± 14.6 versus 58.9 ± 14.9 years; p = 0.014),
while iron deficiency anaemia (112/316 cases, 35.4%) was more common in females (16.9% versus 10.0%;
p = 0.039) and in younger patients (56.8 ± 16.6 versus 60.2 ± 14.6 years; p = 0.043). The prevalence of iron
deficiency was equally distributed between anaemic and non-anaemic patients (p = 0.9). Anisocytosis
(odds ratio: 10.65, 95% confidence interval: 6.13–18.50, p < 0.0001) was independently associated with
anaemia. Conclusions: Anaemia is a common manifestation in AAG patients, mostly due to micronutrient
deficiencies. Scant haematologic alterations and micronutrient deficiencies may precede overt anaemia.
Keywords: anisocytosis; iron deficiency; pernicious anaemia; vitamin B12
1. Introduction
Autoimmune atrophic gastritis (AAG) is an organ-specific, immune-mediated disorder that
affects the corpus and fundus of the stomach, causing atrophy of the oxyntic mucosa, impaired
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gastric acid secretion, and intrinsic factor deficiency [1,2]. AAG is a relatively frequent condition,
particularly in elderly individuals, even if any age group may be affected [3–5]. In the natural history
of AAG, malabsorption of micronutrients, especially vitamin B12 and iron, occurs over time [6,7].
Micronutrient deficiencies lead to various manifestations, in particular, red blood cell alterations,
which may represent the sole clinical presentation of AAG [4–8]. A diagnosis of AAG can be easily
made in case of overt pernicious anaemia [9,10]. However, according to a previous study of ours [4],
a considerable proportion of AAG patients have scant and subtle haematological alterations, including
isolated mean corpuscular volume (MCV) changes and isolated increase of red cell distribution
width (RDW). A high proportion of AAG patients may also suffer from iron deficiency anaemia long
before the onset of vitamin B12 deficiency, or may present a dimorphic anaemia as a consequence
of combined deficiency [6]. According to previous observational studies, the prevalence of anaemia
in patients with AAG ranges from 19% to 94% (Table 1) [4,6,11–18]. However, despite the relevant
clinical burden, ad hoc studies focusing on red blood cell alterations in large cohorts of patients with
histologically-confirmed AAG are lacking. As we have recently shown, haematological alterations
might be overlooked, especially in female patients and in non-haematological settings, determining
substantial AAG diagnostic delay [18,19].
Table 1. Main studies reporting the prevalence of anaemia in adult patients with autoimmune atrophic
gastritis (AAG).
Authors Year Setting Patients (n)
Enrolled
at AAG
Diagnosis
Mean
Age
(years)
Overall
Anaemia
(%)
PA (%) IDA (%) Major Findings
Burman et al. [11] 1991 Internalmedicine 86 Yes 56 80.2 80.2 NA
High PCA levels
associated with PA
Hersko et al. [6] 2006 Haematology 160 NS 59 75.0 18.1 51.8
Microcytic anaemia
more common
in younger age
Lahner et al. [12] 2009 Gastroenterology 165 Yes 54 94.5 49.0 45.5
PCA and anti-intrinsic
factor antibodies yield
73% accuracy PA
diagnosis
Miceli et al. [4] 2012 Gastroenterology 99 Yes 58 59.6 59.6 0
PA was the most
common cause of AAG
diagnosis
Lahner et al. [13] 2015 Gastroenterology 83 Yes 59 51.8 51.8 NA
A genetic variant
of transcobalamin 2 was
related to PA
Zhang et al. [14] 2017 Gastroenterology 275 Yes 61 19.3 5.4 8.4
No clear gender
differences; microcytic
anaemia more common
in younger age
Kalkan et al. [15] 2017 Gastroenterology 355 NS 57 30.1 30.1 NA PA more commonin older patients
Carabotti et al. [16] 2017 Gastroenterology 379 Yes 55 88.4 53.6 34.8
PA more frequent
in patients without
gastrointestinal
symptoms
Villanacci et al. [17] 2017 Pathology 138 NS 48 54.7 25.0 29.7 IDA more commonthan PA
Lenti et al. [18] 2019 Gastroenterology 291 Yes 60 49.5 23.4 11.7
Isolated MCV alterations
associated with greater
AAG diagnostic delay
Abbreviations: IDA, iron deficiency anaemia; MCV, mean corpuscular volume; NA, not assessed; NS, not specified;
PA, pernicious anaemia; PCA, anti-parietal cell antibody. Studies exploring atrophic gastritis prior to H. pylori
discovery were not included. Mean age refers to anaemic patients only, whenever this datum is available.
On these bases, the primary aim of this cross-sectional study was to assess the prevalence and
types of anaemia and micronutrient deficiencies, according to age and gender, in AAG patients at
the time of diagnosis. The secondary aim was to identify patterns of red blood cell alterations and
putative predictors of anaemia. Lastly, recovery from anaemia at a one-year follow-up was evaluated
in a subgroup of AAG patients.
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2. Materials and Methods
2.1. Participating Centres, Patient Selection, and Definition of Anaemia
Four Italian, tertiary referral centres for the diagnosis and management of AAG participated in this
study (Istituto di Ricovero e Cura a Carattere Scientifico San Matteo Hospital in Pavia, Sant’Andrea
Hospital in Rome, IRCCS Ca’ Granda Hospital in Milan, and IRCCS National Cancer Institute
in Aviano). In these centres, most Italian adult AAG patients are referred and followed-up. Each centre
has a dedicated database in which relevant data, including sociodemographic characteristics and
medical history, have been prospectively collected from all consecutive adult AAG patients over the
last ten years. According to internationally agreed criteria, AAG diagnosis was based on histological
grounds following the updated Sydney–Houston criteria [20]. The presence of AAG-related serum
antibodies, namely anti-parietal cell antibodies (PCA) and anti-intrinsic factor antibodies, was not
considered a necessary feature in case of clear and undoubted histological lesions [21]. In fact, these
antibodies have no absolute accuracy for AAG, and may not be present in late disease stage [12,22,23]
In all cases, gastric biopsy specimens were reviewed from expert gastrointestinal pathologists.
Histopathological alterations consistent with any stage of AAG include: (i) atrophy of gastric oxyntic
mucosa, (ii) absence of atrophy in gastric antrum mucosa, (iii) concurrent evidence of extensive intestinal
and/or pseudopyloric metaplasia, and (iv) hyperplasia of gastrin-producing cells and hyperplasia
of enterochromaffin-like cells. Patients with uncertain AAG diagnosis (e.g., patchy or uncertain
mucosal lesions), active H. pylori infection, atrophic pangastritis, and with incomplete medical history,
were not included in the study. All data from adult (≥18 years old) AAG patients were anonymised and
collated onto a predefined spreadsheet. All queries regarding uncertain data were resolved via email
or meetings through consensus with the study coordinators (MVL, EL). Particularly, demographic
and clinical data from patients’ medical records were collected and analysed, including gender, age,
main clinical presentation, comorbidities, and histopathological features according to Operative Link
on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment
(OLGIM) [24,25]. Relevant laboratory data at the time of AAG diagnosis (±1 month) were collected,
including haemoglobin, MCV (normal range 80–98 femtoliter), RDW (normal range 11–15%), platelets
(normal range 150,000–450,000/microliter), serum vitamin B12 (deficient if < 200 ng/L), iron (deficient if
< 55 ng/mL), ferritin (deficient if < 30 ng/mL), folate (deficient if < 4 ng/mL), homocysteine (increased if
> 12 µmol/L), and presence or absence of serum PCA [26]. Complete blood counts were performed by
a Cell-Dyn Sapphire. Vitamin B12 was assessed in serum by an automated immunochemistry analyser,
which is a solid-phase, competitive chemiluminescent enzyme immunoassay. PCA were detected by
either immunofluorescence or enzyme-linked immunosorbent assay (ELISA) techniques. Iron, ferritin,
and folate were detected by a colorimetric assay. Homocysteine was assessed with a fluorometric assay
kit in plasma or serum. Anaemia was classified according to the World Health Organisation (WHO),
i.e., haemoglobin < 120 g/L in females and < 130 g/L in males living at sea level [27]. Transferrin,
reticulocytes, inflammatory markers (e.g., C reactive protein), and urine methylmalonic acid were
not included in the final analyses, as they were missing in many patients. Iron deficiency anaemia
was defined as the presence of anaemia and low iron and ferritin levels, while pernicious anaemia
was defined as the presence of macrocytic anaemia (or normocytic in case of dimorphic anaemia)
and vitamin B12 and/or folate deficiency. Anaemia of chronic disease was inferred in case of ferritin
> 100 ng/mL and iron < 55 ng/mL. A few patients with concomitant haematological disorders were
excluded a priori, as it was not possible to ascertain the aetiology of red blood cell alterations.
In a subgroup of 181 patients belonging to the Pavia cohort, for whom cell blood count was available
after 12 months since diagnosis, one-year follow-up data were reported. The study was approved
by each local Ethics Committee and all patients gave their informed consent for the anonymised
publication of data. The results of this study are reported according to the STrengthening the Reporting
of OBservational studies in Epidemiology (STROBE) recommendations.
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2.2. Statistical Analysis
A descriptive statistical analysis was performed for clinical features, and data were expressed as
number of total and/or percentage or mean± standard deviation (SD). Some variables were not available
for all records, and these were excluded for percentage calculation. Comparison amongst groups at
univariate analysis was performed by Chi-squared test. Multivariate logistic regression analyses were
used to identify variables related to the dependent variables of interest (any type of anaemia, pernicious
anaemia, and iron deficiency anaemia) by including as cofactors all demographic, haematological,
and clinical variables of interests. For the logistic regression model, the overall model fit was considered
(significant difference of the null model −2 Log Likelihood and the full model −2 Log Likelihood by
Chi-Squared test), and the Hosmer and Lemeshow test, a statistical test for goodness of fit for the
logistic regression model, was performed, with a p-value < 0.05 indicating poor fit and a p-value > 0.05
indicating a good logistic regression model fit. Each logistic regression model was run by using
the methods “Enter”, “Forward”, “Backward”, and “Stepwise” to enter the independent variables
into the model. Variables were removed if p > 0.1. Associations of cofactors with the independent
variable were taken into consideration when statistical significance was present in all models and
were expressed by odds ratio (OR) and 95% confidence intervals (95% CI). The Chi-squared test was
performed between age groups and gender, and within age groups. Two-tailed p values less than 0.05
were considered statistically significant. Statistical analyses were performed with a dedicated software
(MedCalc Software, Mariakerke, Belgium, version 12.7.8).
3. Results
3.1. Demographic, Clinical, and Histopathological Characteristics
A computerised database with records of 817 patients was initially set up (Figure 1). After a careful
review, 163 patients were excluded because they did not match the inclusion criteria or because
of missing data. Thus, the total number of enrolled patients was 654 (mean age 59.2 ± 13.8 years, female:
male ratio = 2.3:1), for whom at least the baseline complete cell blood count and clinical presentation
were available. Other variables were not available for all patients, hence statistical analyses were
preformed after exclusion of patients with missing data, as detailed in the tables. Of these, 287 patients
(43.9%) were from Pavia, 268 (41.0%) from Rome, 74 (11.3%) from Milan, and 25 (3.8%) from Aviano.
Relevant demographic and clinical data are reported in Table 2. Indeed, more than one sign, symptom,
or alteration may have occurred in the same patient. Female gender was predominant, and 470 patients
(71.8%) were aged > 50 years. No statistical difference emerged between male and female gender when
plotted according to age groups. 295 patients (46.8%) suffered from another concomitant autoimmune
disease, which was autoimmune thyroid disease in most cases (251 patients; 39.9%). Other less common
autoimmune diseases included type 1 diabetes, vitiligo, psoriasis, coeliac disease, and primary biliary
cholangitis. According to the Sydney–Houston criteria, the mean severity score of corpus atrophy
(information available for 549/654 patients) was 2.6 ± 0.6. Operative Link on Gastritis Assessment
(OLGA) scores 1 and 2 were observed in 52 (9.4%) and 497 (90.5%) patients, respectively. Gastric corpus
intestinal metaplasia was present in 437 (79.6%) patients, with a mean severity score of 1.2 ± 0.8,
whereas Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) scores 1, 2, and 3 were
present in 208 (37.8%), 225 (40.9%), and 4 (0.7%) patients, respectively. Pseudopyloric metaplasia was
seen in 409 (62.5%) patients.
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Figure 1. Flowchart of the study. Patients were excluded as per study design. Of the 654 included
patients, cell blood count data of 181 (88 anaemic, 93 not anaemic) patients at one-year follow-up were
reported. Abbreviations: AAG, autoimmune atrophic gastritis; Hp, H. pylori.
Table 2. Main demographic and clinical features of patients with autoimmune atrophic gastritis (AAG).
Demographic Features
Total AAG patients, n 654
Females, n (%) 459 (70.2)
Age (years), median (range) 61 (18–88)
Main clinical presentation at diagnosis, n (%)
Haematological 368 (56.3)
Gastrointestinal 109 (16.7)
Neuropsychiatric 105 (16.1)
Endocrinological 23 (3.5)
Miscellaneous 53 (8.1)
Other relevant clinical information, n (%)
Current or past smoking 246 (37.7)
Cardiovascular disease 384 (58.7)
Autoimmune comorbidities 305 (46.7)
Neuropsychiatric disorders 180 (27.5)
Family history of AAG 55 (8.4)
Family history of gastric cancer 16 (2.4)
Proton pump inhibitor use prior to diagnosis 237 (36.3)
Previously treated H. pylori infection 97 (14.8)
3.2. Haematological Alterations
Haematological alterations were the leading cause of AAG diagnosis (Table 2). Overall, the mean
haemoglobin level was 116 ± 26 g/L, the mean MCV was 90.7 ± 16 fL, and the mean RDW was
15.9% ± 4.3%. The mean platelet count was 236.9 ± 95.4/microliter, while thrombocytopenia or
thrombocytosis were observed in 92 (15.2%) and in 13 (2.1%) patients, respectively. Anaemia,
which was observed in 316 patients (48.3%; mean age 60.1 ± 15.8 years, F:M ratio = 2.3:1), was mild
(haemoglobin ≥ 95 g/L) in 194 patients (61.4%), moderate (haemoglobin 80–94 g/L) in 52 patients
(16.4%), and severe (haemoglobin < 80 g/L) in 70 patients (22.2%). Figure 2 reports the proportion
of patients with and without anaemia (A), according to MCV (B), and subtypes of anaemia (C). Patients
with anaemia had a significantly higher prevalence of MCV abnormalities, anisocytosis, vitamin B12
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and folate deficiency, and thrombocytopenia in comparison to non-anaemic patients. Table 3 reports all
relevant demographic, clinical, haematological, and histological variables of AAG patients according
to the presence or absence of anaemia (any type). With regards to non-anaemic patients, MCV and
RDW alterations were present in 76 (23.9%) and in 113 (39.1%) cases, respectively. A significantly
higher prevalence of gastrointestinal symptoms, autoimmunity, and treated H. pylori infection was
also seen in non-anaemic compared to anaemic patients (Table 3).
Figure 2. The study population includes 654 adult patients suffering from autoimmune atrophic
gastritis. The figure shows the proportion of patients with and without anaemia (A), the distribution
of mean corpuscular volume (MCV) in anaemic patients (B), and subtypes of anaemia (C). The category
“Others” includes chronic kidney failure and neoplastic diseases. Abbreviations: ACD, anaemia of
chronic disease; IDA, iron deficiency anaemia; PA, pernicious anaemia.
Table 3. Clinical, haematological, and histological variables of patients with autoimmune atrophic
gastritis (AAG) according to the presence or absence of anaemia (any type).
Presence of Anaemia Absence of Anaemia p-Value
Female gender 220/459 (47.9) 239/459 (52.1) 0.8916
Male gender 96/195 (49.2) 99/195 (50.8) 0.9563
Age (years) mean ± SD 60.1 ± 15.8 59.3 ± 13.9 0.5061
Age groups (years)
≥80 31 (10.0) 10 (3.0)
Trend 0.5463
70–79 74 (23.9) 82 (24.8)
60–69 64 (20.6) 89 (26.8)
50–59 47 (15.2) 73 (22.0)
40–49 61 (19.7) 41 (12.3)
30–39 24 (7.7) 32 (9.6)
≤29 9 (2.9) 5 (1.5)
Current or past smoking 103/300 (34.3) 114/324 (35.2) 0.8894
Gastrointestinal symptoms 32/302 (10.6) 75/310 (24.2) <0.0001
Endocrinological disorders 7/302 (2.3) 16/312 (5.1) 0.1050
Cardiovascular disease 178/301 (59.1) 188/317 (59.3) 0.9674
Neuropsychiatric disorders 80/297 (26.9) 90/313 (28.7) 0.6816
Autoimmune comorbidities 130/305 (42.6) 165/325 (50.8) 0.0491
Autoimmune thyroid disease 108/303 (35.6) 143/325 (44.0) 0.0399
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Table 3. Cont.
Presence of Anaemia Absence of Anaemia p-Value
Family history of AAG 19/296 (6.4) 33/314 (10.5) 0.1136
Family history of gastric cancer 6/296 (2.0) 9/314 (2.9) 0.6838
PPI use prior to diagnosis 63/216 (29.2) 97/223 (43.5) 0.0025
Previous H. pylori infection 26/276 (9.4) 61/311 (19.6) 0.0008
Macrocytosis 108/303 (35.6) 48/317 (15.1) <0.0001
Microcytosis 105/303 (34.6) 28/317 (8.8) <0.0001
Normocytosis 90/303 (29.7) 241/317 (76.0) <0.0001
Vitamin B12 deficiency 167/278 (60.1) 124/303 (40.9) <0.0001
Iron deficiency 163/280 (58.2) 164/286 (57.3) 0.9007
Folate deficiency 24/165 (14.5) 10/201 (4.9) 0.0031
Vitamin B12 and iron deficiency 72/263 (27.4) 64/279 (22.9) 0.2749
Increased RDW 227/277 (81.9) 113/289 (39.1) <0.0001
Thrombocytopenia 69/294 (23.5) 23/310 (7.4) <0.0001
Thrombocytosis 6/294 (2.0) 7/310 (2.2) 0.9231
Intestinal metaplasia 246/310 (79.3) 258/332 (77.7) 0.6814
Pseudopyloric metaplasia 196/301 (65.1) 194/317 (61.2) 0.3547
OLGA 1
OLGA 2
22/269 (8.2)
247/269 (91.8)
30/280 (10.7)
250/280 (89.3) Trend 0.3851
OLGIM 0
OLGIM 1
OLGIM 2
OLGIM 3
56/269 (20.8)
102/269 (37.9)
111/269 (41.3)
0 (0)
56/280 (20.0)
106/280 (37.9)
114/280 (40.7)
4/280 (1.4)
Trend 0.6349
Abbreviations: OLGA, Operative Link for Gastritis Assessment; OLGIM, Operative Link on Gastric Intestinal
Metaplasia Assessment; PPI, proton pump inhibitor; RDW, red blood cell distribution width; SD, standard deviation.
Percentages were calculated after exclusion of patients with missing data. p < 0.0001 were more frequent in females.
Combined pernicious and iron deficiency anaemia was similarly distributed between genders (13.3% versus 9.1%;
p = 0.1970). Thrombocytopenia was nearly two-fold more common in males compared to females (21.2% versus
12.7%; p = 0.0108). Finally, folate deficiency (16% versus 6.5%; p = 0.007) and hyperhomocysteinaemia (63.2% versus
45.9%; p = 0.0011) were both more frequent in males.
3.3. Micronutrient Deficiencies
Regardless of anaemia, vitamin B12 deficiency was observed in 291 (50.1%) patients and iron
deficiency in 327 (57.8%) patients. Combined vitamin B12 and iron deficiency was present in 136 (25.1%)
cases. Folate deficiency was seen in 34 (9.3%) patients and was associated with vitamin B12 or iron
deficiency in 17 (2.6%) and 4 (0.6%) cases, respectively. Folate deficiency anaemia, without concurrent
iron or vitamin B12 deficiency, was not observed at all. Patients with anaemia had a significantly higher
prevalence of vitamin B12 and folate deficiency compared to non-anaemic patients, while iron deficiency
was equally distributed between the two groups (Table 3). Hyperhomocysteinaemia was equally
distributed between anaemic and non-anaemic patients (50.6% versus 51.7; p = 0.778). Regarding
non-anaemic patients, at least one micronutrient deficiency was present in 224/338 (66.3%) cases.
3.4. Haematological Alterations with Regard to Gender
In all AAG patients, while normocytosis was equally distributed between genders, microcytosis
occurred more frequently in females (24.0% versus 15.5%; p = 0.0237) and macrocytosis more frequently
in males (36.4% versus 20.3%; p < 0.0001). Pernicious anaemia (27.1% versus 12.4%; p = 0.0015) and
vitamin B12 deficiency without anaemia (56.3% versus 46.8%; p = 0.0448) were more frequent in males,
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while iron deficiency anaemia (16.9% versus 10.0%; p = 0.0393) and iron deficiency without anaemia
(64.4% versus 40.9%) were more frequent in females. Combined pernicious and iron deficiency anaemia
was similarly distributed between genders (13.3% vs. 9.1%; p = 0.1970). Thrombocytopenia was nearly
twofold more common in males compared to females (21.2% vs. 12.7%; p = 0.0108). Finally, folate
deficiency (16% vs. 6.5%; p = 0.007) and hyperhomocysteinaemia (63.2% vs. 45.9%; p = 0.0011) were
both more frequent in males.
3.5. Haematological Alterations with Regard to Age (as a Continuous Variable)
Overall, AAG patients with microcytosis were younger (54.7 ± 15.5 versus 61.1 ± 14.5 years;
p < 0.0001), while those with macrocytosis were older (63.2 ± 13.8 versus 58.5 ± 15.1; p = 0.0008).
Patients with iron deficiency anaemia (56.8 ± 16.6 versus 60.2 ± 14.6 years; p = 0.0436) and combined
pernicious and iron deficiency anaemia (55.9 ± 15.3 versus 60.2 ± 14.9 years; p = 0.0211) were younger,
while patients with pernicious anaemia were older (63.0 ± 14.6 versus 58.9 ± 14.9 years; p = 0.0144).
Finally, hyperhomocysteinaemia (61.3 ± 15.1 versus 57.6 ± 15.2 years; p = 0.0101) was more commonly
observed in older patients.
3.6. Clinical Predictors of Anaemia
Table 4 shows multivariable results for all possible factors associated with anaemia (any type),
pernicious anaemia, and iron deficiency anaemia. At logistic regression analysis, anaemia (any type)
was significantly associated with anisocytosis, thrombocytopenia, absence of gastrointestinal symptoms,
and no proton pump inhibitor use. Moreover, iron deficiency anaemia was significantly associated with
anisocytosis and absence of thrombocytopenia, while pernicious anaemia was significantly associated
with anisocytosis, thrombocytopenia, and no history of H. pylori infection.
Table 4. Multivariate logistic regression analysis for variables associated with anaemia (any type),
iron deficiency anaemia, and pernicious anaemia in patients with autoimmune atrophic gastritis (AAG).
Variables Odds Ratio 95% CI p-Value
Autoimmune comorbidities 0.67 0.2306–1.9532 0.4644
No history of H. pylori infection 1.48 0.7288–3.0118 0.2775
Thrombocytopenia 3.27 1.4596–7.3507 0.0040
Increased RDW 10.65 6.1381–18.5012 <0.0001
Absence of gastrointestinal symptoms 2.26 1.1048–4.6312 0.0256
Autoimmune thyroid disease 0.92 0.3127–2.7167 0.8825
Vitamin B12 deficiency 1.09 0.6359–1.8960 0.7371
No PPI use prior to diagnosis 1.98 1.1071–3.5423 0.0213
PCA positivity 0.92 0.4873–1.7438 0.8024
Age < 50 years 0.67 0.3830–1.1922 0.1760
Family history of gastric cancer 0.45 0.0823–2.5594 0.3744
No family history of AAG 1.77 0.7096-4.4185 0.2207
Current or past smoking 0.78 0.4638-1.3122 0.3494
Autoimmune comorbidities 0.51 0.1683-1.5950 0.2517
No history of H. pylori infection 1.69 0.8029-3.5970 0.1657
Absence of thrombocytopenia 2.20 1.0789-4.5053 0.0301
Increased RDW 4.83 2.7097-8.6409 <0.0001
Female gender 1.47 0.8227-2.6430 0.1921
PCA positivity 1.39 0.6535-2.9741 0.3900
Age < 50 years 0.66 0.3372-1.3286 0.2511
No family history of AAG 1.26 0.4861-3.3118 0.6266
Current or past smoking 1.13 0.6082-2.1290 0.6860
Autoimmune comorbidities 0.60 0.1775-2.0391 0.4145
No history of H. pylori infection 2.98 1.1249-7.9012 0.0280
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Table 4. Cont.
Variables Odds Ratio 95% CI p-Value
Thrombocytopenia 3.51 1.7113-7.2044 0.0006
Increased RDW 6.40 3.1210-13.1643 <0.0001
Female gender 0.33 0.38 to 1.42 0.3663
Abbreviations: PCA, anti-parietal cell antibody; RDW, red cell distribution width. The analysis included 549 patients
with complete data.
3.7. Follow-Up of Anaemia
In a sub-cohort of 181 AAG patients (mean age 59.2± 14.6 years, F:M ratio = 2.7:1), we compared cell
blood count at diagnosis and after treatment of anaemia according to current recommendations [5,7,28].
All patients received parenteral supplementation of vitamin B12 and oral folic acid, and serum levels
were normal at one year in all cases. Oral daily iron supplementation with different commercially
available formulations was the first-line treatment of iron deficiency, while only three patients
required an intravenous formulation. As shown in Figure 3A, a significantly (p < 0.0001) lower
proportion of anaemic patients was observed at the one-year follow-up in comparison to baseline.
Remarkably, stratification of anaemic patients according to MCV significantly (p = 0.003) changed after
therapy, with complete recovery of macrocytosis (Figure 3B). The proportion of anaemic patients with
anisocytosis significantly (p < 0.0001) decreased after treatment (Figure 3C). Regarding patients with
persistent microcytic anaemia only, this was mild in all cases, with depletion of iron stores despite
oral supplementation.
Figure 3. Sub-analysis of a cohort of 181 patients (mean age 59.2 ± 14.6 years, female: male ratio = 2.7:1)
who were followed-up for at least one year. The figure shows the proportion of patients with and without
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anaemia at diagnosis and at the one-year follow-up (A), the distribution of mean corpuscular volume
(MCV) in anaemic patients at diagnosis and at the one-year follow-up (B), and the distribution of red
cell distribution width (RDW) at diagnosis and at the one-year follow-up (C). Abbreviations: RDW, red
cell distribution width.
4. Discussion
Here we have reported red blood cell alterations in a large cohort of patients with histologically
proven AAG at the time of diagnosis. Roughly half of AAG patients were anaemic, being pernicious
anaemia and iron deficiency anaemia the most prevalent subtypes, with gender- and age-related
differences. Anisocytosis was the strongest predictor of anaemia. Of note, a considerable proportion
of non-anaemic AAG patients showed micronutrient deficiencies.
Recently, the clinical burden of anaemia in a number of immune-mediated gastrointestinal
disorders, including inflammatory bowel disease and coeliac disease, has gained a great interest [29,30].
With regards to AAG, only one study specifically focused on patterns of anaemia and haematologic
alterations in biopsy unproven AAG, and only patients who were referred for iron deficiency anaemia
or vitamin B12 deficiency were enrolled [6]. In this study, some cases of chronic gastritis without
atrophy and active H. pylori infection were also included. Moreover, the prevalence of anaemia and
related haematologic alterations in AAG have been described in other series, but only as a part of the
general clinical description (see Table 1). Our study reveals that haematologic alterations are the leading
reasons for AAG diagnosis. Recently, we have also shown that AAG diagnosis could be delayed
partly due to the lack of physician awareness, especially among gastroenterologists, of all possible
clinical presentations of this condition [18]. Compared to the presence of overt anaemia, diagnostic
delay was longer for scant haematologic alterations (<12 months versus 12–24 months), including
isolated microcytosis and macrocytosis. Hence, these subtle alterations should not be overlooked
and should prompt further investigations, starting from AAG serological tests [31]. According to
previous reports [7,28,32], AAG should be ruled out in all cases of vitamin B12 deficiency and
in case of unexplained iron deficiency anaemia. Our data provide further background for supporting
this strategy.
Half of AAG patients were anaemic at the time of diagnosis. The crude prevalence of pernicious
anaemia was similar to that of iron deficiency anaemia but was different when adjusted for gender and
age. Particularly, iron deficiency anaemia was more common in younger female patients, whereas
pernicious anaemia was more common in older male patients. These findings may be explained
by the slow evolution of AAG, that may take several years to progress [1,33,34]. It is reasonable
to assume that iron deficiency characterises earlier disease stages, in which hypo-achlorhydria causes
iron malabsorption, even if additional unknown immunological factors may have a role. Conversely,
vitamin B12 is stored in large amounts and it takes years for pernicious anaemia to develop.
From a pathophysiological point of view, there should be no differences between female and
male AAG patients with regard to iron absorption. However, a possible explanation could be
that iron deficiency is more likely in women of reproductive age, due to menstrual blood loss.
In premenopausal women, menstrual flow per se is a possible confounding factor, frequently causing
iron deficiency anaemia, and postmenopausal status is often able to reverse mild anaemia [35].
Data regarding menstrual cycle and menopause were not available, hence no firm conclusion can be
drawn in this regard.
The inclusion of patients at different time points of AAG natural history may also explain other
findings. Unexpectedly, there seems to be no correlation between anaemia and severity of histological
damage, according to both OLGA and OLGIM classifications. Even patients showing severe gastric
corpus atrophy might have been enrolled at any time after development of the histological changes.
This could also explain the high prevalence of vitamin B12 deficiency, iron deficiency, or a combination
of both in patients without anaemia, possibly reflecting the enrolment at an early disease stage.
However, mechanisms other than gastric mucosal atrophy could explain our findings. For example,
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the role of other factors, including hypo-achlorhydria, bacterial overgrowth, impairment of iron
metabolism, and immunological alterations secondary to AAG still needs to be elucidated.
At multivariate analysis, anisocytosis was the strongest predictor of anaemia. Interestingly,
increased RDW has been associated with a higher all-cause mortality rate in the general population [36].
The association of anaemia with the lack of gastrointestinal symptoms is less clear but could reflect
a longer diagnostic delay [18] that may favour the occurrence of anaemia. Instead, the association
of pernicious anaemia with the lack of H. pylori infection may underlie the pathogenic difference
between AAG and post-infectious atrophic gastritis. However, there is still ongoing debate in this
regard, with contrasting results [37], and more studies are needed to ascertain this hypothesis. To sum
up these results, in clinical practice, the sole presence of anisocytosis should raise the suspicion of AAG,
while no other clear predictors were found.
According to the one-year follow-up, most cases of anaemia recovered. Particularly, pernicious
anaemia recovered in all cases, while a proportion of patients still had iron deficiency anaemia.
These data seem to indicate that iron deficiency anaemia might take more time to recover and oral iron
supplementation therapy might fail to restore iron storage adequately.
Some limitations of the study must be mentioned. First, patients might have been diagnosed at
different times of AAG natural course, thus affecting the prevalence of haematologic alterations. Also,
transferrin and laboratory inflammatory markers were not available in our series. Further, our study
did not evaluate the clinical impact of anaemia in terms of disabling symptoms, including fatigue
and malaise. Nonetheless, this is the largest cohort of AAG patients that has been described so far,
showing that overt anaemia and subtle red blood cell alterations are frequent and are the leading cause
of AAG diagnosis.
5. Conclusions
More attention should be paid to scant haematologic alterations, most commonly due to vitamin
B12 and iron deficiency. Prompt micronutrient supplementation is warranted in AAG patients, as could
prevent (or revert) the development of anaemia. Optimal treatment of iron deficiency anaemia still
needs to be defined.
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